Neurogene (NGNE) News
NASDAQ: NGNEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
26.40-0.10 (-0.38%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
NGNE news summary
We found 2 recent headlines mentioning Neurogene (NGNE): 2 in the past week and 2 in the past 30 days, most often from Nasdaq, Seeking Alpha. For price context, NGNE is down 0.38% at $26.40. The most recent story, "JP Morgan Initiates Coverage of Neurogene at Overweight", was published by Nasdaq on Oct 8, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Neurogene headlines
- JP Morgan Initiates Coverage of Neurogene at OverweightFintel reports that on October 8, 2026, JP Morgan initiated coverage of Neurogene (NASDAQGM:NGNE) (DB:UU8) with a Overweight recommendation.Prior to this rating action, the stock closed at $25.87 on…Nasdaq
- Neurogene is a new Overweight at J.P. Morgan on Rett syndrome therapySeeking Alpha